Integrum

Integrum occupies a specialized position in medical devices at the intersection of orthopedic implants, prosthetics, and neurotechnology. Its core differentiation is the OPRA Implant System, which creates a direct bone-anchored connection between an implant and an external prosthesis rather than relying on a conventional socket. The company also extends its platform into e-OPRA, which investigates implanted electrodes, neuromuscular interfaces, intuitive control, and sensory feedback. More than 500 OPRA surgeries have reportedly been performed across fourteen countries since 1990, giving Integrum a substantial clinical history for a highly focused product category. Its market opportunity is constrained by surgical complexity, rehabilitation requirements, regulatory approvals, and specialist-center capacity. Integrum’s distribution agreement with Bionics Group Ukraine and its Centers of Excellence strategy suggest that market access depends as much on care infrastructure and clinician training as on the implant itself. The company’s public listing provides financing access, while its small employee base limits execution capacity relative to diversified device manufacturers.

Integrum’s trajectory reflects a transition from research-led development toward broader commercial execution. Founded in 1998 and publicly listed in 2017, the company has built a focused portfolio around the OPRA Implant System, with e-OPRA and Neuromotus extending its longer-term neuroprosthetics ambitions. A distribution agreement with Bionics Group Ukraine announced on Jun 3, 2025 created a route to expand access in that market, while the Aug 13, 2025 Global Collaborative Congress sponsorship supported clinical education and professional visibility. Leadership changes mark a major inflection point: Martin Hillsten became CEO on May 5, 2025, Louise Wåhlin became CFO on Sep 15, 2025, and a broader organizational restructuring was announced on Oct 23, 2025. The February 2026 reorganization further emphasized commercialization, supply-chain efficiency, and Centers of Excellence. Financing has remained active, including a $4.77 million post-IPO equity round in 2024, a $0.74 million post-IPO debt round in 2025, and a $2.18 million directed share issue in September 2026. The main growth constraint is converting clinical adoption into repeatable international sales while managing capital needs and operational complexity.